Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.4% – Here’s What Happened

Zenas BioPharma, Inc. (NASDAQ:ZBIO)’s stock price fell 6.4% during trading on Monday . The company traded as low as $39.68 and last traded at $39.77. 51,600 shares were traded during trading, a decline of 80% from the average session volume of 255,240 shares. The stock had previously closed at $42.49.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ZBIO shares. Morgan Stanley raised their price target on shares of Zenas BioPharma from $34.00 to $37.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Evercore ISI assumed coverage on shares of Zenas BioPharma in a research report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective for the company. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research note on Tuesday, December 16th. Wall Street Zen raised Zenas BioPharma from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $52.00 price target on shares of Zenas BioPharma in a research report on Monday, October 27th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $46.29.

Zenas BioPharma Trading Down 5.6%

The business has a 50 day simple moving average of $35.20 and a 200-day simple moving average of $23.05. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of -5.68 and a beta of -1.62.

Zenas BioPharma (NASDAQ:ZBIO) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Buying and Selling at Zenas BioPharma

In other news, insider Leon O. Moulder, Jr. acquired 36,928 shares of the firm’s stock in a transaction dated Tuesday, October 7th. The stock was bought at an average price of $20.85 per share, with a total value of $769,948.80. Following the transaction, the insider directly owned 36,928 shares in the company, valued at approximately $769,948.80. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Sr One Capital Management, Llc purchased 126,315 shares of Zenas BioPharma stock in a transaction that occurred on Thursday, October 9th. The shares were acquired at an average price of $19.00 per share, with a total value of $2,399,985.00. Following the acquisition, the insider directly owned 1,917,895 shares of the company’s stock, valued at $36,440,005. This trade represents a 7.05% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 923,035 shares of company stock valued at $17,628,163 in the last ninety days. Insiders own 16.50% of the company’s stock.

Hedge Funds Weigh In On Zenas BioPharma

Several large investors have recently modified their holdings of the stock. Federated Hermes Inc. increased its stake in shares of Zenas BioPharma by 60.8% during the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after purchasing an additional 703,838 shares during the period. Vanguard Group Inc. increased its stake in Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after acquiring an additional 170,546 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after buying an additional 16,461 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of Zenas BioPharma in the 3rd quarter valued at approximately $3,237,000. Finally, Millennium Management LLC acquired a new stake in Zenas BioPharma in the third quarter valued at approximately $1,595,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.